Charles Schwab Corp. has recently had its valuation adjusted, with its current price at $97.27. The company has shown strong performance over the past year with a 29.26% return, outperforming the S&P 500. Key financial metrics such as a P/E ratio of 20 and a promising PEG ratio of 0.42 highlight its competitive position and growth potential within the capital markets sector.

Bar Harbor Wealth Management significantly increased its stake in Texas Pacific Land Corporation (NYSE:TPL) by 195.1% in the fourth quarter, acquiring 24,379 additional shares to hold a total of 36,873 shares valued at approximately $10.59 million. This increase makes their holding about 0.05% of the company. Texas Pacific Land recently reported strong quarterly earnings, beating estimates with an EPS of $1.79 and revenue of $211.6 million, and subsequently announced an increased quarterly dividend of $0.60 per share, leading to an 8.5% jump in stock price.

Bar Harbor Wealth Management reduced its stake in Union Pacific Corporation by 10.1%, selling 4,670 shares but still holding 41,645 shares valued at approximately $9.63 million. This comes as Union Pacific's EVP Eric J. Gehringer also sold shares, and the company reported missing quarterly EPS estimates. Despite this, Union Pacific maintains a "Moderate Buy" consensus rating from analysts with an average target price of $265.86.

Azarias Capital Management L.P. has reduced its stake in Standard Motor Products (NYSE:SMP) by selling 27,054 shares, bringing their total ownership to 151,941 shares, representing about 2.5% of their portfolio. This comes as Standard Motor Products reported strong Q4 results, beating EPS estimates, and increased its quarterly dividend to $0.33 per share, resulting in a 3.5% yield. The company currently holds a "Moderate Buy" consensus rating from analysts with an average target price of $49.00.

Bar Harbor Wealth Management has increased its stake in Merck & Co., Inc. by 7.2%, bringing its total holdings to 172,032 shares valued at $18.11 million. This makes Merck the firm's 24th largest holding, representing 1.0% of its portfolio. Despite insider selling totaling $38.28 million over the last 90 days, analysts maintain a "Moderate Buy" consensus with a target price of $127.59, supported by recent upgrades from several banks.

Bartlett & CO. Wealth Management LLC reduced its stake in Bristol Myers Squibb by 11.8% in Q4 2025, now holding 134,602 shares valued at $7.26 million. Separately, EVP David V. Elkins sold 30,000 BMY shares on April 1 at an average price of $61.67, decreasing his position by 15.85%. Bristol Myers Squibb reported Q4 EPS of $1.26, missing estimates, and set FY2026 guidance between $6.05 and $6.35 EPS, while also declaring a quarterly dividend of $0.63 per share.

Bar Harbor Wealth Management significantly reduced its stake in Brown & Brown, Inc. by 57.1%, now holding shares valued at $3.74 million. Other institutional investors like AQR Capital Management LLC and Arrowstreet Capital Limited Partnership increased their positions, while Wall Street analysts maintain a "Hold" rating with a consensus price target of $84.47. Brown & Brown recently beat EPS estimates and reported strong revenue growth, alongside paying a quarterly dividend.

Bartlett & CO. Wealth Management LLC increased its stake in Cincinnati Financial Corporation (CINF) by 11.2% in Q4 2025, now holding 131,755 shares valued at $21.63 million. This increase follows Cincinnati Financial's strong Q4 performance, where it surpassed earnings and revenue expectations and announced a dividend increase. The company's stock shows a market cap of $25.09 billion and a moderate buy consensus rating among analysts.

Bartlett & CO. Wealth Management LLC reduced its stake in Lowe's Companies by 1.5% in Q4, holding 513,091 shares valued at approximately $123.74 million. Other hedge funds increased their holdings in Lowe's during the same period. Lowe's exceeded Q4 earnings expectations with an EPS of $1.98 and revenue of $20.59 billion, and announced a quarterly dividend of $1.20 per share.

Citigroup Global Markets Australia and related Citi group entities have informed Telix Pharmaceuticals that they are no longer a substantial holder in the company as of April 8, 2026. This change is primarily due to net reductions in their holdings via adjustments in securities lending agreements. Although the overall stake has fallen below the substantial holder threshold, the shifts are considered technical, stemming from routine trading and lending, rather than a strategic move.